Welcome to our dedicated page for DOMINARI HOLDINGS news (Ticker: DOMH), a resource for investors and traders seeking the latest updates and insights on DOMINARI HOLDINGS stock.
Dominari Holdings Inc. (DOMH) delivers cutting-edge developments in biotechnology and financial services through its diversified operations. This news hub provides investors and stakeholders with timely updates on the company’s therapeutic research, market activities, and strategic initiatives.
Access comprehensive coverage of DOMH’s progress in oncology drug development, including updates on clinical trials targeting pancreatic cancer and leukemia. Track financial services milestones through Dominari Securities LLC’s underwriting activities and technology investments in AI infrastructure.
The page consolidates official press releases covering earnings reports, partnership announcements, and regulatory developments. Users will find verified information on therapeutic advancements, capital market participation, and emerging technology ventures.
Bookmark this resource for streamlined access to DOMH’s latest achievements in small-molecule research and financial market operations. Regularly updated content ensures informed decision-making for all stakeholders monitoring this innovative holding company.
Dominari Holdings Inc. (Nasdaq: DOMH) announced an update on its $2 million share repurchase program, initiated on December 5, 2022. The company purchased 5,000 shares at $4.2658 per share on March 2, 2023. Future repurchases will depend on market conditions, corporate strategies, and regulatory limitations. Dominari, previously focused on anticancer and antiviral therapeutics, is transitioning to fintech through its subsidiary, Dominari Financial Inc. The company remains involved in its therapeutic ventures via Aikido Labs, LLC.
Dominari Holdings Inc. (Nasdaq: DOMH) announced updates on its $2 million share repurchase program authorized on December 5, 2022. As of February 28, 2023, the Company repurchased 4,603 shares at $3.7434 per share. The repurchase may continue periodically, influenced by market conditions and regulatory limitations. The Company, rebranded from Aikido Pharma, is transitioning its focus to fintech through its subsidiary, Dominari Financial Inc., while still pursuing therapeutic development via Aikido Labs, LLC. This dual focus aims to enhance long-term shareholder value.
Dominari Holdings Inc. (Nasdaq: DOMH) announced an update regarding its $2 million share repurchase program authorized on December 5, 2022. On February 27, 2023, the company bought 4,855 shares at $3.6941 per share. Further repurchases may occur based on market conditions and regulatory limitations. Dominari, formerly focused on therapeutics, is transitioning to fintech services through its subsidiary, Dominari Financial Inc., while still developing its healthcare portfolio through Aikido Labs, LLC.
Dominari Holdings Inc. (Nasdaq: DOMH) announced on February 22, 2023 that it has executed a buyback of 5,000 shares at $3.8612 per share as part of its $2 million Share Repurchase Program initiated on December 5, 2022. The company plans to continue repurchasing shares periodically depending on market conditions and regulatory limitations. This initiative is expected to enhance shareholder value and reflects the company’s commitment to returning capital to its investors. Dominari, transitioning to a fintech and financial services focus, continues to develop its therapeutics through its subsidiary.
Dominari Holdings Inc. (Nasdaq: DOMH) announced an update on its $2 million share repurchase program initiated on December 5, 2022. As of February 16, 2023, the Company repurchased 5,000 shares at $3.8475 each. The repurchase will continue based on market conditions and regulatory limits. Dominari is transitioning from its focus on therapeutics to fintech and financial services following an acquisition. The subsidiary, Dominari Financial Inc., will manage these new operations, while Aikido Labs, LLC will continue developing therapeutics.
Dominari Holdings Inc. (Nasdaq: DOMH) announced an update on its $2 million share repurchase program initiated on December 5, 2022. As of February 14, 2023, the company has repurchased 4,600 shares at an average price of $4.0804 per share. The company may continue to buy back shares through open market transactions, depending on market conditions and regulatory constraints. Dominari has shifted focus from developing therapeutics to fintech and financial services following its acquisition of a registered broker-dealer, with operations expected under its subsidiary, Dominari Financial Inc.
Dominari Holdings Inc. (Nasdaq: DOMH) announced an update on its $2 million share repurchase program authorized on December 5, 2022. On February 10, 2023, the company repurchased 3,000 shares at a price of $3.9073 per share. The share repurchase will continue based on market conditions and regulatory constraints, which may affect timing and volume. Dominari is shifting its primary focus to fintech and financial services, following its acquisition of a registered broker-dealer, while still developing its therapeutics portfolio through its subsidiary Aikido Labs, LLC.
Dominari Holdings Inc. (Nasdaq: DOMH) provided an update on its $2 million share repurchase program authorized on December 5, 2022. On February 7, 2023, the Company repurchased 5,000 shares at $4.0475 per share. The repurchase will continue subject to market conditions and regulatory limitations. Dominari, previously focused on therapeutics, is transitioning to fintech and financial services following a registered broker-dealer acquisition. The transition will occur through its subsidiary, Dominari Financial Inc., while therapeutics will continue through Aikido Labs, LLC.
Dominari Holdings (DOMH) announced an update on its $2 million share repurchase program initiated on
Dominari Holdings Inc. (Nasdaq: DOMH) announced an update regarding its $2 million share repurchase program authorized on December 5, 2022. On February 1, 2023, the company repurchased 4,701 shares at an average price of $3.8211 per share. The company plans to continue repurchasing shares based on market conditions and regulatory requirements. Following a strategic shift from developing therapeutics to fintech operations, the company remains committed to its subsidiary, Aikido Labs, LLC, while enhancing shareholder value through this buyback program.
FAQ
What is the current stock price of DOMINARI HOLDINGS (DOMH)?
What is the market cap of DOMINARI HOLDINGS (DOMH)?
